ITRM
- Iterum Therapeutics plc
()
Overview
Company Summary
Iterum Therapeutics plc (ITRM) is a pharmaceutical company that specializes in the development and commercialization of innovative anti-infectives for patients suffering from serious and life-threatening infections. The company's primary focus is on developing novel antibiotics and addressing the global issue of antibiotic resistance.
Iterum's team uses its expertise in infectious diseases to identify and advance potential drug candidates through clinical trials. The company's efforts are centered around providing solutions for multi-drug resistant gram-negative bacteria, such as E. coli, Klebsiella pneumonia, and Pseudomonas aeruginosa, which are known to cause various healthcare-associated infections.
By leveraging its technology and research capabilities, Iterum aims to develop effective and safe antibiotics to combat these resistant pathogens. The company's portfolio includes drugs like sulopenem, which is an oral and intravenous formulation designed to target a broad spectrum of gram-negative bacteria. Other drug candidates in Iterum's pipeline include oral formulations for uncomplicated urinary tract infections and intravenous formulations for complicated urinary tract infections and complicated intra-abdominal infections.
Iterum Therapeutics primarily operates in the United States and is committed to addressing the significant unmet medical needs in infectious diseases. Through its research and development efforts, the company strives to offer healthcare professionals and patients effective treatment options for serious infections where current therapies may be inadequate.
Please note that company strategies and pipeline developments may change over time, and it is always advisable to refer to the latest information from Iterum Therapeutics for the most accurate and up-to-date details about their operations.